Company news

Share this article:

Neurogen is taking a charge of about $1.5 million in the first quarter of 2008 in connection with laying off 70 workers. The payments will cover severance benefits and other charges. According to Neurogen, the move is part of a restructuring to focus resources on advancing its pipeline of insomnia and other compounds including Phase II candidate aplindore for Parkinson's disease and restless legs syndrome.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.